Company intelligence

BBNX

Price—Latest market price

Market cap—Equity value

P / E—Trailing ratio

Volume—Latest session

Market data

BBNX price chart

TradingView

Related signals

1 min delayed

Browse public BBNX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

BBNXAug 21, 2026+1.48% since signal

William Blair Initiates Coverage on Beta Bionics and Tandem Diabetes Care

William Blair initiated coverage on Beta Bionics (BBNX) and Tandem Diabetes Care (TNDM), highlighting their push into faster-growing insulin pump segments. The move could lift BBNX’s visibility and attract investor interest, though no targets or metrics were provided. The catalyst hinges on analyst coverage, with potential near-term volatility tied to market acceptance of new pump technologies.

View signal analysis

BBNXJan 9, 2026-13.83% since signal

Beta Bionics Key KPI Miss Targets, Analyst Flags Valuation Risks

BBNX expects Q4 sales of at least $32 million, exceeding consensus. Installed user base projected to exceed 35,000, doubling last year's figures. BofA downgraded BBNX from Buy to Neutral, citing valuation and new patient start issues. Analyst lowered BBNX price forecast from $33 to $28 amid competitive pressures. Company sees growing adoption among Type 2 diabetes patients, boosting overall market.

View signal analysis

Research